Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child
Doctors treated a boy with rare leukemia and spinal pressure using special drugs
This is a case report with a systematic review of 11 published cases of TTMV::RARA-positive acute promyelocytic leukemia (APL). The authors …
A nine-year-old boy had rare leukemia and spinal cord pressure. Doctors used specific drugs that helped clear the disease and fix his spine.
Review of ATRA and ATO induction therapy in acute promyelocytic leukemia with RNA sequencing insights
Why PCR Missed This Leukemia
This case report and literature review examines induction therapy using all-trans retinoic acid and arsenic trioxide in acute promyelocytic …
A standard blood test missed a dangerous leukemia because the disease had a unique genetic pattern that routine screening overlooked until a…
Phase II trial shows high remission and survival with frontline ATRA-ATO for newly diagnosed APL
Can a chemotherapy-free treatment beat a rare, aggressive leukemia?
A prospective multicenter phase II trial in 81 newly diagnosed APL patients in Japan found that frontline ATRA-ATO therapy achieved a 95.1% …
A chemotherapy-free treatment for acute promyelocytic leukemia achieved 95% remission and 95% survival three years later in a Japanese trial…
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort
Can a simple blood test help diagnose leukemia? An AI tool shows promise but still needs work
An AI tool was tested on a retrospective, international cohort of 6206 leukemia patients from 20 centers to predict acute leukemia subtypes …
An AI tool can spot leukemia from standard blood tests but must refuse to guess for most patients until doctors refine it to help more peopl…
Research across Leukemia
Related studies from across the Leukemia family.
Early genetic diagnosis of inherited bone marrow failure syndromes facilitates timely transplant and lifelong surveillance
Genetic Factors May Influence Diagnosis of Bone Marrow Failure
This narrative review explores the pathogenesis, clinical manifestations, and management of pediatric patients with inherited bone marrow fa…
Genetic factors can be the hidden cause of bone marrow failure in children, making early genetic testing vital for proper treatment and plan…
Positive LSC status is associated with inferior survival outcomes in patients with acute myeloid leukemia
Leukemia Stem Cell Counts Help Doctors Predict Patient Survival Outcomes
This systematic review and reconstructed individual patient data meta-analysis analyzed survival outcomes in patients with acute myeloid leu…
Testing for specific leukemia stem cells can help doctors predict how well a patient will do during treatment.
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
Icotinib Treatment for Lung Cancer Linked to Rare Blood Condition
This case report and literature review describes a 75-year-old female with lung adenocarcinoma treated with icotinib. The report identifies …
A rare case of acute myeloid leukemia was linked to a specific lung cancer treatment, highlighting the need for regular blood monitoring.
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL
Trial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL
In Ph-positive ALL, frontline ponatinib plus blinatumomab achieved 86% 24-month event-free survival versus 67% with imatinib plus chemothera…
A new combination of ponatinib and blinatumomab showed higher survival rates and fewer relapses for adults with Philadelphia-positive ALL.
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds
Vancomycin-resistant Enterococcus is common in patients with certain blood cancers
This meta-analysis of 120 studies estimates the pooled prevalence of vancomycin-resistant Enterococcus (VRE) in patients with hematological …
A large review of 120 studies shows that nearly 1 in 5 patients with leukemia or lymphoma carry a resistant strain of bacteria.
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML
Low-dose chemotherapy shows similar results for some children with leukemia
This retrospective secondary analysis of a multicenter randomized controlled trial evaluated low-dose chemotherapy (LDC) versus standard-dos…
A study of children with a specific type of leukemia found that lower doses of chemotherapy can be as effective as standard doses for many p…
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Dasatinib therapy in pediatric ALL may cause chylothorax and Bartonella henselae infection
Dasatinib May Cause Chylothorax and Cat-Scratch Disease in Leukemia
This case report and systematic review describes a 14-year-old boy with Ph+ acute lymphoblastic leukemia treated with dasatinib who develope…
A 14-year-old on dasatinib for leukemia developed chylothorax and cat-scratch disease, a rare double complication.
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL
Trial shows blinatumomab improves survival for children with high-risk leukemia
Blinatumomab significantly improves 4-year event-free survival in children with high-risk B-cell ALL compared to standard chemotherapy.
A new trial shows that blinatumomab helps more children with high-risk B-cell leukemia stay healthy compared to standard chemotherapy.
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL
Busulfan Shows Survival Benefits for Patients with Acute Myeloid Leukemia
This meta-analysis of 26 studies compared Busulfan-based conditioning to total body irradiation for children and young adults undergoing hem…
Busulfan may offer better survival for certain leukemias while reducing long-term side effects like growth issues and cataracts in young pat…
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia
Exercise May Help Kids With Leukemia Feel and Move Better
This best evidence summary synthesizes 16 systematic reviews and 2 clinical practice guidelines regarding exercise interventions for childre…
Exercise may improve bone strength, fitness, and quality of life in children with acute leukemia, a new evidence summary suggests.
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML
Specific gene mutations linked to worse outcomes in certain leukemia
This meta-analysis of 4,363 patients found that MRG mutations (such as ASXL1, BCOR, and EZH2) are associated with inferior overall survival …
New data shows that specific gene mutations can predict poorer survival and lower remission rates for patients with a specific type of leuke…
Questions about Acute Promyelocytic Leukemia
How effective is frontline ATRA-ATO therapy for newly diagnosed Acute Promyelocytic Leukemia?
Frontline ATRA-ATO therapy is highly effective for newly diagnosed APL, with complete remission rates over 94% and 3-year survival above 93% in clinical trials.
Full answer →Does the new AI test work well for distinguishing Acute Promyelocytic Leukemia from other types?
An AI tool shows very high accuracy for distinguishing Acute Promyelocytic Leukemia (APL) from other leukemias, with an AUROC of 0.98 in international tests, though it currently excludes many patients from predictions.
Full answer →What are the survival rates for Acute Promyelocytic Leukemia treated with ATRA and ATO?
ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.
Full answer →